Cargando…

Pharmacokinetic/Pharmacodynamic Analysis of Savolitinib plus Osimertinib in an EGFR Mutation–Positive, MET-Amplified Non–Small Cell Lung Cancer Model

Osimertinib is a third-generation, irreversible, oral EGFR tyrosine kinase inhibitor (TKI) recommended as first-line treatment for patients with locally advanced/metastatic EGFR mutation–positive (EGFRm) non–small cell lung cancer (NSCLC). However, MET amplification/overexpression is a common acquir...

Descripción completa

Detalles Bibliográficos
Autores principales:	Jones, Rhys D.O., Petersson, Klas, Tabatabai, Areya, Bao, Larry, Tomkinson, Helen, Schuller, Alwin G.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Association for Cancer Research 2023
Materias:	Models and Technologies
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10157363/ https://www.ncbi.nlm.nih.gov/pubmed/36888921 http://dx.doi.org/10.1158/1535-7163.MCT-22-0193

Ejemplares similares

Acquired Resistance to Osimertinib Plus Savolitinib Is Mediated by MET-D1228 and MET-Y1230 Mutations in EGFR-Mutated MET-Amplified Lung Cancer
por: Piper-Vallillo, Andrew J., et al.
Publicado: (2020)

Osimertinib + Savolitinib to Overcome Acquired MET-Mediated Resistance in Epidermal Growth Factor Receptor–Mutated, MET-Amplified Non–Small Cell Lung Cancer: TATTON
por: Hartmaier, Ryan J., et al.
Publicado: (2023)

Mechanisms of Acquired Resistance to Savolitinib, a Selective MET Inhibitor in MET-Amplified Gastric Cancer
por: Frigault, Melanie M., et al.
Publicado: (2020)

Efficacy and Imaging-Enabled Pharmacodynamic Profiling of KRAS G12C Inhibitors in Xenograft and Genetically Engineered Mouse Models of Cancer
por: Lee, Catherine, et al.
Publicado: (2023)

Brief Report: Clinical Response, Toxicity, and Resistance Mechanisms to Osimertinib Plus MET Inhibitors in Patients With EGFR-Mutant MET-Amplified NSCLC
por: Wang, Kaiwen, et al.
Publicado: (2023)

Brief Report: Heterogeneity of Acquired Resistance Mechanisms to Osimertinib and Savolitinib
por: Lim, Sun Min, et al.
Publicado: (2021)

Local Treatment of a Pediatric Osteosarcoma Model with a 4-1BBL Armed Oncolytic Adenovirus Results in an Antitumor Effect and Leads to Immune Memory
por: Martinez-Velez, Naiara, et al.
Publicado: (2022)

Development of a High-throughput NanoBRET Screening Platform to Identify Modulators of the RAS/RAF Interaction
por: Durrant, David E., et al.
Publicado: (2021)

Oncolytic Vaccinia Virus Gene Modification and Cytokine Expression Effects on Tumor Infection, Immune Response, and Killing
por: Inoue, Tomoyoshi, et al.
Publicado: (2021)

Therapeutic Synergy in Esophageal Cancer and Mesothelioma Is Predicted by Dynamic BH3 Profiling
por: Surman, Deborah R., et al.
Publicado: (2021)

Anti-CD19 CAR T Cells That Secrete a Biparatopic Anti-CLEC12A Bridging Protein Have Potent Activity Against Highly Aggressive Acute Myeloid Leukemia In Vitro and In Vivo
por: Rennert, Paul D., et al.
Publicado: (2021)

FGFR4-Targeted Chimeric Antigen Receptors Combined with Anti-Myeloid Polypharmacy Effectively Treat Orthotopic Rhabdomyosarcoma
por: Sullivan, Peter M., et al.
Publicado: (2022)

Novel Group C Oncolytic Adenoviruses Carrying a miRNA Inhibitor Demonstrate Enhanced Oncolytic Activity In Vitro and In Vivo
por: Doerner, Johannes, et al.
Publicado: (2022)

CD74-NRG1 Fusions Are Oncogenic In Vivo and Induce Therapeutically Tractable ERBB2:ERBB3 Heterodimerization
por: Werr, Lisa, et al.
Publicado: (2022)

B7-H3 Specific CAR T Cells for the Naturally Occurring, Spontaneous Canine Sarcoma Model
por: Zhang, Shihong, et al.
Publicado: (2022)

Transcription Factor–Forced Astrocytic Differentiation Impairs Human Glioblastoma Growth In Vitro and In Vivo
por: Trovato, Francesco, et al.
Publicado: (2023)

An Oncolytic Poxvirus Encoding hNIS, Shows Antitumor Efficacy and Allows Tumor Imaging in a Liver Cancer Model
por: Chaurasiya, Shyambabu, et al.
Publicado: (2023)

Intracranial Activity of Osimertinib Plus Capmatinib in a Patient With EGFR and MET-Driven Lung Cancer: Case Report
por: Gautschi, Oliver, et al.
Publicado: (2021)

Acquired savolitinib resistance in non-small cell lung cancer arises via multiple mechanisms that converge on MET-independent mTOR and MYC activation
por: Henry, Ryan E., et al.
Publicado: (2016)

Savolitinib versus crizotinib for treating MET positive non‐small cell lung cancer
por: Miao, Kang, et al.
Publicado: (2023)

Savolitinib ± Osimertinib in Japanese Patients with Advanced Solid Malignancies or EGFRm NSCLC: Ph1b TATTON Part C
por: Yoh, Kiyotaka, et al.
Publicado: (2021)

Osimertinib Rechallenge With Bevacizumab vs. Chemotherapy Plus Bevacizumab in EGFR-Mutant NSCLC Patients With Osimertinib Resistance
por: Cui, Qingli, et al.
Publicado: (2022)

Pharmacokinetic and Pharmacodynamic Modeling of Serum Etrolizumab and Circulating β7 Receptor Occupancy in Patients With Ulcerative Colitis
por: Wei, Xiaohui, et al.
Publicado: (2017)

Advanced HCC with amplified mesenchymal epithelial transition factor receptor responds well to savolitinib: a case report
por: Yan, Ningning, et al.
Publicado: (2023)

Landscape of Savolitinib Development for the Treatment of Non-Small Cell Lung Cancer with MET Alteration—A Narrative Review
por: Zhu, Xiaokuan, et al.
Publicado: (2022)

Combination of Docetaxel Plus Savolitinib in Refractory Cancer Patients: A Report on Phase I Trial
por: Kim, Seung Tae, et al.
Publicado: (2019)

MET amplification results in heterogeneous responses to osimertinib in EGFR‐mutant lung cancer treated with erlotinib
por: Nishiyama, Akihiro, et al.
Publicado: (2020)

Corrigendum: Advanced HCC with amplified mesenchymal epithelial transition factor receptor responds well to savolitinib: a case report
por: Yan, Ningning, et al.
Publicado: (2023)

Savolitinib: A Promising Targeting Agent for Cancer
por: Lee, Tae Seung, et al.
Publicado: (2023)

Phase Ia/Ib Study of the Selective MET Inhibitor, Savolitinib, in Patients with Advanced Solid Tumors:  Safety, Efficacy, and Biomarkers
por: Wang, Yakun, et al.
Publicado: (2022)

Case Report: Prompt Response to Savolitinib in a Case of Advanced Gastric Cancer With Bone Marrow Invasion and MET Abnormalities
por: Ye, Wen, et al.
Publicado: (2022)

Case Report: A Lung Adenocarcinoma With Brain Metastasis Harbored Novel MET 14 Skipping Alteration Sensitive to Savolitinib
por: Li, Jian, et al.
Publicado: (2022)

Dramatic response and acquired resistance to savolitinib in advanced intrahepatic cholangiocarcinoma with MET amplification: a case report and literature review
por: Zhou, Kexun, et al.
Publicado: (2023)

Long-Term Efficacy, Safety, and Subgroup Analysis of Savolitinib in Chinese Patients With NSCLCs Harboring MET Exon 14 Skipping Alterations
por: Lu, Shun, et al.
Publicado: (2022)

Efficacy of Savolitinib vs Sunitinib in Patients With MET-Driven Papillary Renal Cell Carcinoma: The SAVOIR Phase 3 Randomized Clinical Trial
por: Choueiri, Toni K., et al.
Publicado: (2020)

Significant role of savolitinib in a case of advanced gastric cancer with abnormal mesenchymal‐epithelial transition factor (MET): A case report
por: He, XinCheng, et al.
Publicado: (2022)

Therapeutic effect of osimertinib plus cranial radiotherapy compared to osimertinib alone in NSCLC patients with EGFR-activating mutations and brain metastases: a retrospective study
por: Zhai, Xiaoyang, et al.
Publicado: (2021)

Generation and Characterization of a New Preclinical Mouse Model of EGFR-Driven Lung Cancer with MET-Induced Osimertinib Resistance
por: Mancini, Maicol, et al.
Publicado: (2021)

Response and acquired resistance to savolitinib in a patient with pulmonary sarcomatoid carcinoma harboring MET exon 14 skipping mutation: a case report
por: Han, Sen, et al.
Publicado: (2019)

Use of savolitinib as neoadjuvant therapy for non–small cell lung cancer patient with MET exon 14 skipping alterations: A case report
por: Zhang, Yu, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_dh8hjdv1pikc3hlmrktndah5ko